Podcast: Stepping into the future of protein with Steakholder Foods

Technology

Podcast: Stepping into the future of protein with Steakholder Foods

Partner content

10 December 2024

Podcast: Stepping into the future of protein with Steakholder Foods

In this latest podcast with FoodBev’s Jake Targett, Arik Kaufman, CEO & co-founder of Steakholder Foods (NASDAQ: STKH), explores the cutting-edge advancements shaping the future of food production.

Steakholder Foods is making waves with their industrial-scale 3D-printing technology, designed to meet the evolving needs of food manufacturers and set a new standard in the industry.

Through innovative precision layering techniques, their state-of-the-art fish and meat printers are redefining how plant-based and cultivated proteins can be produced at scale, combining efficiency with creativity to unlock new possibilities in food manufacturing.

Arik delves into the technical aspects of 3D food printing, offering insights into its potential to transform protein production systems and the broader implications for sustainability and global food supply chains.

#Podcast #SteakholderFoods

Steakholder Foods launches plant-based fish products in Israeli retail market

Steakholder Foods, an innovator in alternative protein production and 3D-printing technologies, has announced the commercial rollout of its first plant-based fish products, including white fish kebabs and salmon patties, now available at select vegan speciality stores across Israel.

Steakholder Foods receives $250,000 grant installment for 3D-printed seafood development

Steakholder Foods has announced the receipt of a $250,000 installment from the Singapore-Israel R&D Foundation (SIIRD).

Engineers develop metamaterials for sustainable meat alternatives

Engineers from The Hebrew University of Jerusalem have unveiled a novel approach to creating whole cuts of meat using advanced metamaterials

Pluri secures $3.5m investment to bolster growth in cell-based technology

Pluri has completed a $3.5m private placement, solidifying its financial position as a player in the cell-based biotechnology sector.